Launched on December 20, 2011, the VanEck Pharmaceutical ETF (PPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.
Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on December 20, 2011.
VanEck Pharmaceutical ETF (NYSEARCA:PPH) exists to give investors broad exposure to the global pharmaceutical industry without the binary risk of betting on a single drug pipeline.
| Capital Markets Industry | Financials Sector | - CEO | NZX Exchange | NZPPHE0001S6 ISIN |
| US Country | - Employees | 1 Jul 2026 Last Dividend | 14 Feb 2012 Last Split | - IPO Date |
The fund is a financial instrument designed to provide investors with a means to gain exposure to the pharmaceutical industry, focusing primarily on U.S. exchange-listed companies. It aims to track the performance of its benchmark index by investing at least 80% of its total assets in securities that are included within this index. This benchmark encompasses common stocks and depositary receipts which cover a range of companies within the pharmaceutical sector, including those considered to be of medium capitalization as well as foreign companies that have their shares listed on a U.S. exchange. The fund is characterized as non-diversified, which means it may invest more of its assets in fewer securities than diversified funds, potentially leading to greater volatility in its price.
The primary product offered by the fund is its investment service focusing on securities that make up its benchmark index. This index is carefully selected to represent a wide array of companies within the pharmaceutical sector, including both domestic and foreign companies listed in the U.S. By doing so, the fund aims to mirror the financial performance of these companies, providing investors with an opportunity to invest in the pharmaceutical industry through a single financial instrument.
This service provides investors with access to a specific segment of the market, the pharmaceutical industry, which is known for its high R&D investment and significant potential for innovation and growth. The fund's focus on companies listed on U.S. exchanges, including those of medium capitalization and foreign entities, offers a diverse range of investment opportunities within this sector. It's designed for investors looking to diversify their portfolio with pharmaceutical stocks without the need to individually research and select stocks.